Abiopharma

🔍 Rodman David Malcom (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 2,170 shares of Common Stock at $16.0 per share (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,974.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,170 shares of Common Stock at $33.27 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,804.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 6,348 shares of Common Stock at $1.08 per share (Direct)
  Date: 2026-01-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 68,152.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,348 shares of Common Stock at $32.3162 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,804.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,170 shares of Stock Option at $16.0 per share (Derivative)
  Date: 2026-01-09 | Code: M | Expires: 2033-02-09 | equity_swap_involved: 0 | shares_owned_after: 28,218.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 6,348 shares of Stock Option at $1.08 per share (Derivative)
  Date: 2026-01-12 | Code: M | Expires: 2032-07-11 | equity_swap_involved: 0 | shares_owned_after: 38,092.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.01 to $32.93. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.